The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments (original) (raw)

• Younossi, Z. M. Non-alcoholic fatty liver disease — a global public health perspective. J. Hepatol. 70, 531–544 (2019).
  Article PubMed Google Scholar
• Byrne, C. D., Patel, J., Scorletti, E. & Targher, G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ 362, k2734 (2018).
  Article PubMed Google Scholar
• Targher, G., Lonardo, A. & Byrne, C. D. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat. Rev. Endocrinol. 14, 99–114 (2018).
  Article CAS PubMed Google Scholar
• Mantovani, A. et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S, 154170 (2020).
  Article PubMed CAS Google Scholar
• Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).
  Article PubMed Google Scholar
• Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 68, 335–352 (2018).
  Article PubMed Google Scholar
• Lonardo, A. et al. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol. 56, 385–396 (2019).
  Article PubMed Google Scholar
• Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).
  Article PubMed Google Scholar
• Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32–42 (2017).
  Article CAS PubMed Google Scholar
• Valenti, L., Bugianesi, E., Pajvani, U. & Targher, G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 36, 1563–1579 (2016).
  Article CAS PubMed Google Scholar
• Hallsworth, K. & Adams, L. A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 1, 468–479 (2019).
  Article PubMed PubMed Central Google Scholar
• Knowler, W. C. et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 374, 1677–1686 (2009).
  Article PubMed Google Scholar
• Lindström, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673–1679 (2006).
  Article PubMed Google Scholar
• DeFronzo, R. A. et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364, 1104–1115 (2011).
  Article CAS PubMed Google Scholar
• Sung, K. C., Jeong, W. S., Wild, S. H. & Byrne, C. D. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35, 717–722 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani, A. P. G., Beatrice, G., Tilg, H., Byrne, C. D. & Targher, G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70, 962–969 (2021).
  Article CAS PubMed Google Scholar
• Morrison, A. E., Zaccardi, F., Khunti, K. & Davies, M. J. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int. 39, 557–567 (2019).
  Article CAS PubMed Google Scholar
• Bjorkstrom, K., Stal, P., Hultcrantz, R. & Hagstrom, H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 1461–1468 (2017).
  Article PubMed CAS Google Scholar
• Nasr, P., Ignatova, S., Kechagias, S. & Ekstedt, M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol. Commun. 2, 199–210 (2018).
  Article CAS PubMed Google Scholar
• Nasr, P., Fredrikson, M., Ekstedt, M. & Kechagias, S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 40, 1069–1078 (2020).
  Article CAS PubMed Google Scholar
• Ampuero, J. et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J. Hepatol. 73, 17–25 (2020).
  Article CAS PubMed Google Scholar
• Bae, J. C. et al. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res. Clin. Pract. 135, 1–6 (2018).
  Article PubMed Google Scholar
• Lee, J. et al. The impact of NAFLD and waist circumference changes on diabetes development in prediabetes subjects. Sci. Rep. 9, 17258 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• Cho, H. J. et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus. Gut liver 13, 440–449 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Brunner, K. T. et al. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int. 40, 1339–1343 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Fukuda, T. et al. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur. J. Gastroenterol. Hepatol. 28, 1443–1449 (2016).
  Article CAS PubMed Google Scholar
• Yamazaki, H., Tsuboya, T., Tsuji, K., Dohke, M. & Maguchi, H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 38, 1673–1679 (2015).
  Article CAS PubMed Google Scholar
• Sung, K. C., Wild, S. H. & Byrne, C. D. Resolution of fatty liver and risk of incident diabetes. J. Clin. Endocrinol. Metab. 98, 3637–3643 (2013).
  Article CAS PubMed Google Scholar
• Zaharia, O. P. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 7, 684–694 (2019).
  Article PubMed Google Scholar
• Zaharia, O. P. et al. Role of patatin-like phospholipase domain-containing 3 gene for hepatocellular lipid content and insulin resistance in diabetes. Diabetes Care 43, 2161–2168 (2020).
  Article CAS PubMed Google Scholar
• Liu, Z. et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J. Hepatol. 73, 263–276 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Dongiovanni, P. et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J. Intern. Med. 283, 356–370 (2018).
  Article CAS PubMed Google Scholar
• Eslam, M. & George, J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat. Rev. Gastroenterol. Hepatol. 17, 40–52 (2020).
  Article PubMed Google Scholar
• Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat. Genet. 49, 1758–1766 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Katsiki, N., Mikhailidis, D. P. & Mantzoros, C. S. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65, 1109–1123 (2016).
  Article CAS PubMed Google Scholar
• Al-Mrabeh, A. et al. Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metab. 31, 233–249.e4 (2020).
  Article CAS PubMed Google Scholar
• Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62 (Suppl. 1), S47–S64 (2015).
  Article PubMed Google Scholar
• Yki-Jarvinen, H. Ceramides: a cause of insulin resistance in nonalcoholic fatty liver disease in both murine models and humans. Hepatology 71, 1499–1501 (2020).
  Article PubMed Google Scholar
• Liao, W., Hui, T. Y., Young, S. G. & Davis, R. A. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J. Lipid Res. 44, 978–985 (2003).
  Article CAS PubMed Google Scholar
• Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366–1374 (2007).
  Article CAS PubMed Google Scholar
• Bechmann, L. P. et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57, 1394–1406 (2013).
  Article CAS PubMed Google Scholar
• Kalhan, S. C. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60, 404–413 (2011).
  Article CAS PubMed Google Scholar
• Legry, V. et al. Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects. J. Clin. Endocrinol. Metab. 102, 3783–3794 (2017).
  Article PubMed Google Scholar
• Caussy, C. et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment. Pharmacol. Ther. 49, 183–193 (2019).
  Article CAS PubMed Google Scholar
• de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657–669 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Grabherr, F., Grander, C., Effenberger, M., Adolph, T. E. & Tilg, H. Gut dysfunction and non-alcoholic fatty liver disease. Front. Endocrinol. 10, 611 (2019).
  Article Google Scholar
• Chavez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679–1694.e3 (2017).
  Article CAS PubMed Google Scholar
• Kuipers, F., Bloks, V. W. & Groen, A. K. Beyond intestinal soap–bile acids in metabolic control. Nat. Rev. Endocrinol. 10, 488–498 (2014).
  Article CAS PubMed Google Scholar
• Han, C. Y. Update on FXR biology: promising therapeutic target? Int. J. Mol. Sci. 19, 2069 (2018).
  Article PubMed Central CAS Google Scholar
• Utzschneider, K. M., Kahn, S. E. & Polidori, D. C. Hepatic insulin extraction in NAFLD is related to insulin resistance rather than liver fat content. J. Clin. Endocrinol. Metab. 104, 1855–1865 (2019).
  Article PubMed Google Scholar
• Wahlstrom, A., Sayin, S. I., Marschall, H. U. & Backhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).
  Article PubMed CAS Google Scholar
• Jiao, Y., Lu, Y. & Li, X. Y. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol. Sin. 36, 44–50 (2015).
  Article CAS PubMed Google Scholar
• Kim, H. & Fang, S. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. Lab. Anim. Res. 34, 140–146 (2018).
  Article PubMed PubMed Central Google Scholar
• Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J. Biol. Chem. 292, 11055–11069 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).
  Article CAS PubMed Google Scholar
• Koliaki, C. et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21, 739–746 (2015).
  Article CAS PubMed Google Scholar
• Ter Horst, K. W. et al. Hepatic diacylglycerol-associated protein kinase Cε translocation links hepatic steatosis to hepatic insulin resistance in humans. Cell Rep. 19, 1997–2004 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Magkos, F. et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444–1446.e2 (2012).
  Article CAS PubMed Google Scholar
• Kumashiro, N. et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 108, 16381–16385 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167–1175 (2016).
  Article CAS PubMed Google Scholar
• Cantley, J. L. et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl Acad. Sci. USA 110, 1869–1874 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Jelenik, T. et al. Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver. Diabetes 66, 2241–2253 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Nardo, A. D. et al. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. Liver Int. 40, 1620–1633 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121, 4222–4230 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sharma, A. X. & Holland, W. L. Adiponectin and its hydrolase-activated receptors. J. Nat. Sci. 3, e396 (2017).
  PubMed PubMed Central Google Scholar
• Turpin, S. M. et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678–686 (2014).
  Article CAS PubMed Google Scholar
• Raichur, S. et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687–695 (2014).
  Article CAS PubMed Google Scholar
• Chaurasia, B. et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 365, 386–392 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Summers, S. A. Could ceramides become the new cholesterol? Cell Metab. 27, 276–280 (2018).
  Article CAS PubMed Google Scholar
• Apostolopoulou, M. et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 41, 1235–1243 (2018).
  Article CAS PubMed Google Scholar
• Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574–582.e1 (2013).
  Article CAS PubMed Google Scholar
• Scorletti, E. et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. J. Hepatol. 63, 1476–1483 (2015).
  Article CAS PubMed Google Scholar
• European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
  Article Google Scholar
• Ghosh-Swaby, O. R. et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 8, 418–435 (2020).
  Article CAS PubMed Google Scholar
• Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S. & Targher, G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 46, 427–441 (2020).
  Article CAS PubMed Google Scholar
• Samuel, V. T. & Shulman, G. I. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 27, 22–41 (2018).
  Article CAS PubMed Google Scholar
• Loomba, R. et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis. Hepatology 72, 1219–1229 (2020).
  Article CAS PubMed Google Scholar
• Bugianesi, E. et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100, 1082–1090 (2005).
  Article CAS PubMed Google Scholar
• Haukeland, J. W. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol. 44, 853–860 (2009).
  Article CAS PubMed Google Scholar
• Lavine, J. E. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305, 1659–1668 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Said, A. & Akhter, A. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann. Hepatol. 16, 538–547 (2017).
  Article CAS PubMed Google Scholar
• Macauley, M. et al. Effect of vildagliptin on hepatic steatosis. J. Clin. Endocrinol. Metab. 100, 1578–1585 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Cui, J. et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J. Hepatol. 65, 369–376 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Fei, Y., Tsoi, M. F. & Cheung, B. M. Y. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc. Diabetol. 18, 112 (2019).
  Article PubMed PubMed Central Google Scholar
• Brunton, S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int. J. Clin. Pract. 68, 557–567 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Petit, J. M. et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD study. J. Clin. Endocrinol. Metab. 102, 407–415 (2017).
  PubMed Google Scholar
• Yan, J. et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 69, 2414–2426 (2019).
  Article CAS PubMed Google Scholar
• Bizino, M. B. et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia 63, 65–74 (2020).
  Article CAS PubMed Google Scholar
• Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).
  Article CAS PubMed Google Scholar
• Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2020).
  Article PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03648554 (2019).
• Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392, 2180–2193 (2018).
  Article CAS PubMed Google Scholar
• Hartman, M. L. et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43, 1352–1355 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03900429 (2021).
• Cusi, K. et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes. Metab. 21, 812–821 (2019).
  Article CAS PubMed Google Scholar
• Eriksson, J. W. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61, 1923–1934 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Latva-Rasku, A. et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 42, 931–937 (2019).
  Article CAS PubMed Google Scholar
• Kuchay, M. S. et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41, 1801–1808 (2018).
  Article CAS PubMed Google Scholar
• Kahl, S. et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43, 298–305 (2020).
  Article CAS PubMed Google Scholar
• Lai, L. L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S. & Chan, W. K. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig. Dis. Sci. 65, 623–631 (2020).
  Article CAS PubMed Google Scholar
• de Boer, R. A. et al. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br. J. Clin. Pharmacol. 86, 1346–1356 (2020).
  Article PubMed PubMed Central CAS Google Scholar
• Harrison S. A., et al. LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: interim analysis of a 12-week, randomized, placebo-controlled, phase 2a study. Liver Meet. https://www.natap.org/2019/AASLD/AASLD_75.htm (2019).
• Zhou, Y. et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J. Clin. Endocrinol. Metab. 105, dgz252 (2020).
  Article PubMed Google Scholar
• Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern. Med. 177, 633–640 (2017).
  Article PubMed PubMed Central Google Scholar
• Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297–2307 (2006).
  Article CAS PubMed Google Scholar
• Aithal, G. P. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176–1184 (2008).
  Article CAS PubMed Google Scholar
• Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).
  Article PubMed Google Scholar
• Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ratziu, V. et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51, 445–453 (2010).
  Article CAS PubMed Google Scholar
• Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159.e5 (2016).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02704403 (2020).
• Kaul, U. et al. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc. Diabetol. 18, 80 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03008070 (2021).
• Joy, T. R. et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J. Gastroenterol. 23, 141–150 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Bolinder, J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97, 1020–1031 (2012).
  Article CAS PubMed Google Scholar
• Ratziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100–110 (2008).
  Article CAS PubMed Google Scholar
• Trauner, M. et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol. Hepatol. 4, 445–453 (2019).
  Article PubMed Google Scholar
• Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
  Article CAS PubMed Google Scholar
• Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184–2196 (2019).
  Article CAS PubMed Google Scholar
• Siddiqui, M. S. et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J. Hepatol. 72, 25–33 (2020).
  Article CAS PubMed Google Scholar
• Pockros, P. J. et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 39, 2082–2093 (2019).
  Article CAS PubMed Google Scholar
• Kim, C. W. et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 26, 394–406.e6 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, W. et al. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 45, 1073–1083 (2017).
  Article CAS PubMed Google Scholar
• Struik, D., Dommerholt, M. B. & Jonker, J. W. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. Curr. Opin. Lipidol. 30, 235–243 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174–1185 (2018).
  Article CAS PubMed Google Scholar
• Harrison, S. A. et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 71, 1198–1212 (2020).
  Article CAS PubMed Google Scholar
• Rinella, M. E. et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J. Hepatol. 70, 735–744 (2019).
  Article CAS PubMed Google Scholar
• Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392, 2705–2717 (2019).
  Article PubMed Google Scholar
• Lawitz, E. J. et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 16, 1983–1991.e3 (2018).
  Article CAS PubMed Google Scholar
• Loomba, R. et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155, 1463–1473.e6 (2018).
  Article CAS PubMed Google Scholar
• Safadi, R. et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12, 2085–2091.e1 (2014).
  Article CAS PubMed Google Scholar
• Ratziu, V. et al. On behalf of the ARREST investigator study group. One-year results of the Global Phase 2b randomized placebo-controlled ARREST trial of aramchol, a stearoyl CoA desaturase modulator in NASH patients. Liver Meet. https://www.natap.org/2018/AASLD/AASLD_222.htm (2018).
• Amin, N. B. et al. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci. Transl Med. 11, eaav9701 (2019).
  Article CAS PubMed Google Scholar
• Harrison, S. A. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394, 2012–2024 (2019).
  Article CAS PubMed Google Scholar
• Ratziu, V. et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR Study. Hepatology 72, 892–905 (2020).
  Article CAS PubMed Google Scholar
• Anstee, Q. M. et al. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp. Clin. Trials 89, 105922 (2020).
  Article PubMed Google Scholar
• Harrison, S. A. et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J. Hepatol. 73, 26–39 (2020).
  Article CAS PubMed Google Scholar
• Harrison, S. A. et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 155, 1140–1153 (2018).
  Article CAS PubMed Google Scholar
• Johnston, M. P., Patel, J. & Byrne, C. D. Multi-drug approaches to NASH: what’s in the development pipeline? Expert Opin. Investig. Drugs 29, 143–150 (2020).
  Article CAS PubMed Google Scholar
• Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
  Article PubMed Google Scholar
• Byrne, C. D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet. Med. 29, 1098–1107 (2012).
  Article CAS PubMed Google Scholar
• Scorletti, E. & Byrne, C. D. Extrahepatic Diseases and NAFLD: the triangular relationship between NAFLD, type 2-diabetes and dysbiosis. Dig. Dis. 34 (Suppl. 1), 11–18 (2016).
  Article PubMed Google Scholar